PD-L1 as a biomarker of response to immune-checkpoint inhibitorsDeborah B. Doroshow, Fred R. Hirsch, Sheena Bhalla et al.|Nature Reviews Clinical Oncology|2021Cited by 1.5k
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsDiana Miao, Eliezer M. Van Allen, Claire A. Margolis et al.|Nature Genetics|2018Cited by 701
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R. Oxnard, Pasi A. Jänne, Yuebi Hu et al.|JAMA Oncology|2018Cited by 689
<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met OverexpressionMark M. Awad, Lynette M. Sholl, Geoffrey R. Oxnard et al.|Journal of Clinical Oncology|2016Cited by 687
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCChristian Rolfo, David R. Gandara, Philip C. Mack et al.|Journal of Thoracic Oncology|2018Cited by 661